Urai Ákos, Váradi András, Szőcs Levente, Komjáti Balázs, Le Rouzic Valerie, Hunkele Amanda, Pasternak Gavril W, Majumdar Susruta, Hosztafi Sándor
Department of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9., Budapest H-1092, Hungary.
Molecular Pharmacology and Chemistry Program and Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA.
Medchemcomm. 2017 Jan 1;8(1):152-157. doi: 10.1039/C6MD00450D. Epub 2016 Oct 18.
It was previously reported that 6β-aminomorphinan derivatives show high affinity for opiate receptors. Novel 6β-heteroarylamidomorphinanes were designed based on the MOR selective antagonist NAP. The 6β-aminomorphinanes were prepared with stereoselective Mitsunobu reaction and subsequently acylated with nicotinic acid and isonicotinic acid chloride hydrochlorides. The receptor binding and efficacy were determined and the analgesic activity was studied . The studies revealed moderate selectivity for MOR. At least two compounds in this series exhibited long-acting analgesic response when administered subcutaneously and intracerebroventricularly. When the substances were given intracerebroventricularly to mice, they showed analgesic potency comparable to morphine.
先前有报道称,6β-氨基吗啡喃衍生物对阿片受体具有高亲和力。基于MOR选择性拮抗剂NAP设计了新型6β-杂芳基酰胺吗啡烷。通过立体选择性Mitsunobu反应制备了6β-氨基吗啡烷,随后用烟酸和异烟酸酰氯盐酸盐进行酰化。测定了受体结合和效能,并研究了镇痛活性。研究揭示了对MOR的中等选择性。该系列中至少有两种化合物皮下和脑室内给药时表现出长效镇痛反应。当这些物质脑室内给予小鼠时,它们显示出与吗啡相当的镇痛效力。